Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 19/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 11/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.86 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744184 | 1.00 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744539 | 0.93 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3 | |
| SCHEMBL21743999 | 0.90 | CYP2D6 (0.81) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21743997 | 0.89 | CYP2D6 (0.80) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744819 | 0.87 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744508 | 0.87 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744346 | 0.87 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744661 | 0.87 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744347 | 0.83 | CYP2D6 (0.71) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 | |
| SCHEMBL21744507 | 0.79 | CYP2D6 (1.00) | CYP2D6CXCR4CYP3A4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CYP2D6 4404/4885CXCR4 1/4885CYP3A4 4527/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CYP2D6 4404/4885CXCR4 1/4885CYP3A4 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.